A5017537551- Renal cell carcinoma treatment
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Urological Disorders and Treatments
- MRI in cancer diagnosis
- Ferroptosis and cancer prognosis
- Testicular diseases and treatments
- Prostate Cancer Treatment and Research
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Pediatric Urology and Nephrology Studies
- Adrenal and Paraganglionic Tumors
- Metastasis and carcinoma case studies
- Genetic and Kidney Cyst Diseases
- Renal and Vascular Pathologies
- Genetic Associations and Epidemiology
- Radiomics and Machine Learning in Medical Imaging
The University of Texas MD Anderson Cancer Center
2014-2023
Stennis Space Center
2021-2023
Fiona Stanley Hospital
2023
Imperial College London
2023
University of Massachusetts Boston
2022
University of Michigan
1998-2021
University of Northampton
2021
University of Nottingham
2021
The University of Texas Health Science Center at Houston
2009-2019
United States Naval Research Laboratory
2019
The literature on upper tract urothelial carcinoma (UTUC) has been limited to small, single center studies. A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated poor prognosis identified.Data 1363 at 12 academic centers collected. All pathologic slides re-reviewed by genitourinary pathologists according strict criteria.Pathologic review revealed renal pelvis location (64%), necrosis (21.6%), lymphovascular invasion (LVI) (24.8%),...
To analyze to what extent histologic subtype is of prognostic importance in renal cell carcinoma based on a large, international, multicenter experience.Four thousand sixty-three patients from eight international centers were included this retrospective study. Histologic (1997 International Union Against Cancer [UICC] criteria tumor response), age, sex, TNM stage, Fuhrman grade, size, Eastern Cooperative Oncology Goup performance status (ECOG PS), and overall survival determined all cases....
To evaluate ability of the University California Los Angeles Integrated Staging System (UISS) to stratify patients with localized and metastatic renal cell carcinoma (RCC) into risk groups in an international multicenter study.4,202 from eight academic centers were classified according UISS, which combines TNM stage, Fuhrman grade, Eastern Cooperative Oncology Group performance status. Distribution UISS categories was assessed overall population each center.The stratified both RCC three...
Purpose To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series patients treated radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Patients Methods Data were collected on 1,453 RNU at 13 academic centers combined into relational database. Pathologic slides rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence tumor cells within an...
Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Herein, we describe the clinical features and outcomes for large series of ACC patients.Retrospective review patients seen at The University Texas MD Anderson Cancer Center from 1998 through 2011.A total 330 median age diagnosis 48.5 years; 12 (3.6%) were under 18 years. Hormonally functioning tumors represented 41.8% (n=138) all cases. Surgical resection primary tumor was done in 275 (83.3%) (45 (16.4%)). For those who...
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy 2015 for aRCC after VEGF-targeting agent. In April 2018, nivolumab ipilimumab, CTLA-4 inhibitor, intermediate- poor-risk, previously untreated aRCC. Then, 2019, combinations therapies...
The roles of long non-coding RNAs in cancer metabolism remain largely unexplored. Here we identify FILNC1 (FoxO-induced RNA 1) as an energy stress-induced by FoxO transcription factors. deficiency renal cells alleviates apoptosis and markedly promotes tumor development. We show that leads to enhanced glucose uptake lactate production through upregulation c-Myc. Upon stress, interacts with AUF1, a c-Myc mRNA-binding protein, sequesters AUF1 from binding mRNA, leading downregulation protein....
Abstract Purpose: Incidence and mortality rates for renal cell carcinoma (RCC) have been rising decades. Unfortunately, the molecular events that support RCC carcinogenesis remain poorly understood. In an effort to gain a better understanding of signaling in clear (cRCC), we investigated antitumor activity secreted frizzled-related protein 1 (sFRP1), negative regulator Wnt signaling. Experimental Design: Genomic profiling cRCC tumors patient-matched normal tissues was done confirmed using...
MicroRNAs (miRNA) are a class of small noncoding RNA molecules that have been implicated in wide variety basic cellular functions through posttranscriptional regulations on their target genes. Compelling evidence has shown miRNAs involved cancer initiation and progression. We hypothesized genetic variations the miRNA machinery genes could be associated with risk renal cell carcinoma.We genotyped 40 single nucleotide polymorphisms (SNP) from 11 processing (DROSHA, DGCR8, XPO5, RAN, DICER1,...
Abstract BACKGROUND: The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high‐grade ureteral renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) who received neoadjuvant chemotherapy followed by surgery. METHODS: study group comprised biopsy‐demonstrated, disease nephrouterectomy from 2004 to 2008, during which time uniformly were considered for chemotherapy. control underwent initial nephroureterectomy 1993 2004, when...
There is relatively little literature on adjuvant chemotherapy after radical nephroureterectomy in patients with upper tract urothelial carcinoma. We determined the incidence of high risk and ensuing effect overall cancer specific survival.Using an international collaborative database we identified 1,390 who underwent for nonmetastatic carcinoma between 1992 2006. Of these cases 542 (39%) were classified as (pT3N0, pT4N0 and/or lymph node positive). These divided into 2 groups, including...
Abstract BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. objective this study was to identify preoperative factors that were prognostic outcome who being considered CN. METHODS: authors conducted a retrospective investigate overall survival (OS) underwent using OS with mRCC did not undergo as...
We created a prognostic tool for the accurate preoperative prediction of nonorgan confined upper tract urothelial carcinoma.A computerized data bank containing comprehensive information on 1,453 patients who underwent radical nephroureterectomy at 13 academic institutions was generated and continuously updated. This study comprised subset 659 in whom all appropriate variables (age, gender, race, symptoms, Eastern Cooperative Oncology Group performance status, primary tumor location,...